|
Title
|
|
|
|
Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30-35 and >35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p < 0.0001) and similar across BMI range groups in the lispro-comparator study and greater for exenatide versus placebo in the placebo-controlled study. Significant weight loss occurred with exenatide across BMI range groups (p < 0.0001), while weight increased with both comparators. Achievement of HbA1c < 7.0% (<53 mmol/mol) without weight gain was greater for exenatide versus comparators. Systolic blood pressure decreased across BMI range groups with exenatide in the lispro-comparator study (p < 0.0001); changes in lipids were not clinically meaningful. Minor hypoglycaemia was less frequent for exenatide versus insulin lispro. These findings suggest that BMI alone should not limit clinical decision-making or patient access to medication. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Diabetes, obesity & metabolism. - Oxford, 1999, currens
|
|
|
Publication
|
|
|
|
Oxford
:
Blackwell
,
2016
|
|
|
ISSN
|
|
|
|
1462-8902
[print]
1463-1326
[online]
|
|
|
DOI
|
|
|
|
10.1111/DOM.12669
|
|
|
Volume/pages
|
|
|
|
18
:8
(2016)
, p. 829-833
|
|
|
ISI
|
|
|
|
000379904300011
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|